Skip to main content
. Author manuscript; available in PMC: 2008 Jul 1.
Published in final edited form as: Cell Immunol. 2007 Jul;248(1):31–43. doi: 10.1016/j.cellimm.2007.03.010

Table 2.

Development of H13a tracheal allograft rejection in H13b recipients

Donor Recipient Time post-Tx (days) Treatment OAD Lesions (% of Allografts)
Epithelial Damage Cellular Infiltration Lumen Occlusion
H13a H13b 30 - 25 25 0
H13a H13b 60 - 100 100 0
H13a H13b 90 - 100 100 100
H13b H13b 30 - 0 0 0
H13b H13b 60 - 0 0 0
H13b H13b 90 - 0 0 0
Pre-transplant sensitization (subcutaneous injection of peptide)
H13a H13b 30 SVL9 100 100 50
H13a H13b 60 SVL9 100 100 75
H13a H13b 90 SVL9 100 100 100
H13a H13b 30 SIL9 25 25 0
H13a H13b 60 SIL9 100 100 0
H13a H13b 90 SIL9 100 100 100
Pre-transplant tolerization (intravenous injection of peptide)
H13a H13b 90 SVL9 0 0 0
H13a H13b 90 SIL9 100 100 100
BALB/c H13b 30 SVL9 100 100 100